Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Islam Hassan

Showing results (21-30 of 29) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 29 results.
Nature Communications|July 20, 2019
Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastomaNabil Elshafeey, Aikaterini Kotrotsou, Ahmed Hassan, et al.
Nucleic Acids Research|November 23, 2023
Europe PMC in 2023Summer Rosonovski, Maria Levchenko, Rajat Bhatnagar, et al.
Nature Medicine|February 24, 2023
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trialIngo K Mellinghoff, Min Lu, Patrick Y Wen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2018
A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft ModelsPascal O Zinn, Sanjay K Singh, Aikaterini Kotrotsou, et al.
Neuro-Oncology|April 6, 2021
Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experienceEudocia Q Lee, Wendy Selig, Clair Meehan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2021
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I TrialIngo K Mellinghoff, Marta Penas-Prado, Katherine B Peters, et al.
Neuro-Oncology|April 5, 2022
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumorsBenjamin M Ellingson, Elizabeth R Gerstner, Andrew B Lassman, et al.
The New England Journal of Medicine|June 5, 2023
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaIngo K Mellinghoff, Martin J van den Bent, Deborah T Blumenthal, et al.
The Lancet. Oncology|November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trialTimothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
Pageof 3

Showing results (21-30 of 29) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 29 results.
Nature Communications|July 20, 2019
Multicenter study demonstrates radiomic features derived from magnetic resonance perfusion images identify pseudoprogression in glioblastomaNabil Elshafeey, Aikaterini Kotrotsou, Ahmed Hassan, et al.
Nucleic Acids Research|November 23, 2023
Europe PMC in 2023Summer Rosonovski, Maria Levchenko, Rajat Bhatnagar, et al.
Nature Medicine|February 24, 2023
Vorasidenib and ivosidenib in IDH1-mutant low-grade glioma: a randomized, perioperative phase 1 trialIngo K Mellinghoff, Min Lu, Patrick Y Wen, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 29, 2018
A Coclinical Radiogenomic Validation Study: Conserved Magnetic Resonance Radiomic Appearance of Periostin-Expressing Glioblastoma in Patients and Xenograft ModelsPascal O Zinn, Sanjay K Singh, Aikaterini Kotrotsou, et al.
Neuro-Oncology|April 6, 2021
Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experienceEudocia Q Lee, Wendy Selig, Clair Meehan, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 3, 2021
Vorasidenib, a Dual Inhibitor of Mutant IDH1/2, in Recurrent or Progressive Glioma; Results of a First-in-Human Phase I TrialIngo K Mellinghoff, Marta Penas-Prado, Katherine B Peters, et al.
Neuro-Oncology|April 5, 2022
Hypothetical generalized framework for a new imaging endpoint of therapeutic activity in early phase clinical trials in brain tumorsBenjamin M Ellingson, Elizabeth R Gerstner, Andrew B Lassman, et al.
The New England Journal of Medicine|June 5, 2023
Vorasidenib in IDH1- or IDH2-Mutant Low-Grade GliomaIngo K Mellinghoff, Martin J van den Bent, Deborah T Blumenthal, et al.
The Lancet. Oncology|November 1, 2025
Vorasidenib in IDH1-mutant or IDH2-mutant low-grade glioma (INDIGO): secondary and exploratory endpoints from a randomised, double-blind, placebo-controlled, phase 3 trialTimothy F Cloughesy, Martin J van den Bent, Mehdi Touat, et al.
Pageof 3